Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-Initiated Trial to Evaluate the Dosimetry, Safety, Tolerability, and Preliminary Efficacy of a Single-Dose [177Lu]Lu-XT771 Injection in Patients With Recurrent Glioblastoma

NCT07648823 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07648823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07648823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-Initiated Trial to Evaluate the Dosimetry, Safety, Tolerability, and Preliminary Efficacy of a Single-Dose [177Lu]Lu-XT771 Injection in Patients With Recurrent Glioblastoma
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
June 20, 2026
Completion date
June 1, 2028
Enrollment
5 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm), recurrent glioblastoma, recurrent glioblastoma (who-grade iv glioma), recurrent glioblastoma idh wildtype